Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco.

<h4>Background</h4>Current laboratory and point-of-care tests for HIV detect different analytes and use different sample types. Some have fast turnaround times (<1 hour). We investigated how HIV test choice could impact case finding by testing programs.<h4>Methods</h4>We a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Christopher D Pilcher, Brian Louie, Shelley Facente, Sheila Keating, John Hackett, Ana Vallari, Chris Hall, Teri Dowling, Michael P Busch, Jeffrey D Klausner, Frederick M Hecht, Sally Liska, Mark W Pandori
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
R
Q
Acceso en línea:https://doaj.org/article/898caf193bd94211b5400e2294bc530d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:898caf193bd94211b5400e2294bc530d
record_format dspace
spelling oai:doaj.org-article:898caf193bd94211b5400e2294bc530d2021-11-18T08:42:19ZPerformance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco.1932-620310.1371/journal.pone.0080629https://doaj.org/article/898caf193bd94211b5400e2294bc530d2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24349007/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Current laboratory and point-of-care tests for HIV detect different analytes and use different sample types. Some have fast turnaround times (<1 hour). We investigated how HIV test choice could impact case finding by testing programs.<h4>Methods</h4>We analyzed 21,234 consecutive HIV tests with venous blood obtained by San Francisco HIV testing programs from 2003 to 2008. For a subset, oral fluid (n = 6446) or fingerstick blood (n = 8127) samples were also obtained for rapid testing. In all cases, HIV status was determined using an HIV antibody-plus-RNA test algorithm. We assessed how the screening antibody tests performed individually versus the gold standard of the full algorithm. We then evaluated the potential ability of other tests (including new tests) to detect more cases, by re-testing all specimens that had negative/discrepant antibody results on initial screening.<h4>Findings</h4>The antibody-RNA algorithm identified 58 acute and 703 established HIV infection cases. 1(st)-generation (Vironostika) and 3(rd)-generation (Genetic Systems) immunoassays had 92 and 96 percent sensitivity, respectively. The Oraquick rapid test had clinical sensitivity of only 86 percent on oral fluid samples, but 92 percent on finger-stick blood. Newer 4(th)-generation, antigen-antibody combo rapid immunoassay (ARCHITECT) detected HIV in 87 percent of all the acute cases that had been missed by one of the previous screening assays. A point-of-care 4(th) generation antigen-antibody combo rapid test (Determine) detected about 54 percent of such acute cases.<h4>Conclusions</h4>Our study suggests that some rapid antibody blood tests will give similar case detection to laboratory antibody tests, but that oral fluid testing greatly reduces ability to detect HIV. New 4(th)-generation combo tests can detect the majority of acute infections detectable by HIV RNA but with rapid results. Using these tests as a primary screening assay in high-risk HIV testing programs could reduce or eliminate the need for HIV RNA testing.Christopher D PilcherBrian LouieShelley FacenteSheila KeatingJohn HackettAna VallariChris HallTeri DowlingMichael P BuschJeffrey D KlausnerFrederick M HechtSally LiskaMark W PandoriPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 12, p e80629 (2013)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Christopher D Pilcher
Brian Louie
Shelley Facente
Sheila Keating
John Hackett
Ana Vallari
Chris Hall
Teri Dowling
Michael P Busch
Jeffrey D Klausner
Frederick M Hecht
Sally Liska
Mark W Pandori
Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco.
description <h4>Background</h4>Current laboratory and point-of-care tests for HIV detect different analytes and use different sample types. Some have fast turnaround times (<1 hour). We investigated how HIV test choice could impact case finding by testing programs.<h4>Methods</h4>We analyzed 21,234 consecutive HIV tests with venous blood obtained by San Francisco HIV testing programs from 2003 to 2008. For a subset, oral fluid (n = 6446) or fingerstick blood (n = 8127) samples were also obtained for rapid testing. In all cases, HIV status was determined using an HIV antibody-plus-RNA test algorithm. We assessed how the screening antibody tests performed individually versus the gold standard of the full algorithm. We then evaluated the potential ability of other tests (including new tests) to detect more cases, by re-testing all specimens that had negative/discrepant antibody results on initial screening.<h4>Findings</h4>The antibody-RNA algorithm identified 58 acute and 703 established HIV infection cases. 1(st)-generation (Vironostika) and 3(rd)-generation (Genetic Systems) immunoassays had 92 and 96 percent sensitivity, respectively. The Oraquick rapid test had clinical sensitivity of only 86 percent on oral fluid samples, but 92 percent on finger-stick blood. Newer 4(th)-generation, antigen-antibody combo rapid immunoassay (ARCHITECT) detected HIV in 87 percent of all the acute cases that had been missed by one of the previous screening assays. A point-of-care 4(th) generation antigen-antibody combo rapid test (Determine) detected about 54 percent of such acute cases.<h4>Conclusions</h4>Our study suggests that some rapid antibody blood tests will give similar case detection to laboratory antibody tests, but that oral fluid testing greatly reduces ability to detect HIV. New 4(th)-generation combo tests can detect the majority of acute infections detectable by HIV RNA but with rapid results. Using these tests as a primary screening assay in high-risk HIV testing programs could reduce or eliminate the need for HIV RNA testing.
format article
author Christopher D Pilcher
Brian Louie
Shelley Facente
Sheila Keating
John Hackett
Ana Vallari
Chris Hall
Teri Dowling
Michael P Busch
Jeffrey D Klausner
Frederick M Hecht
Sally Liska
Mark W Pandori
author_facet Christopher D Pilcher
Brian Louie
Shelley Facente
Sheila Keating
John Hackett
Ana Vallari
Chris Hall
Teri Dowling
Michael P Busch
Jeffrey D Klausner
Frederick M Hecht
Sally Liska
Mark W Pandori
author_sort Christopher D Pilcher
title Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco.
title_short Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco.
title_full Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco.
title_fullStr Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco.
title_full_unstemmed Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco.
title_sort performance of rapid point-of-care and laboratory tests for acute and established hiv infection in san francisco.
publisher Public Library of Science (PLoS)
publishDate 2013
url https://doaj.org/article/898caf193bd94211b5400e2294bc530d
work_keys_str_mv AT christopherdpilcher performanceofrapidpointofcareandlaboratorytestsforacuteandestablishedhivinfectioninsanfrancisco
AT brianlouie performanceofrapidpointofcareandlaboratorytestsforacuteandestablishedhivinfectioninsanfrancisco
AT shelleyfacente performanceofrapidpointofcareandlaboratorytestsforacuteandestablishedhivinfectioninsanfrancisco
AT sheilakeating performanceofrapidpointofcareandlaboratorytestsforacuteandestablishedhivinfectioninsanfrancisco
AT johnhackett performanceofrapidpointofcareandlaboratorytestsforacuteandestablishedhivinfectioninsanfrancisco
AT anavallari performanceofrapidpointofcareandlaboratorytestsforacuteandestablishedhivinfectioninsanfrancisco
AT chrishall performanceofrapidpointofcareandlaboratorytestsforacuteandestablishedhivinfectioninsanfrancisco
AT teridowling performanceofrapidpointofcareandlaboratorytestsforacuteandestablishedhivinfectioninsanfrancisco
AT michaelpbusch performanceofrapidpointofcareandlaboratorytestsforacuteandestablishedhivinfectioninsanfrancisco
AT jeffreydklausner performanceofrapidpointofcareandlaboratorytestsforacuteandestablishedhivinfectioninsanfrancisco
AT frederickmhecht performanceofrapidpointofcareandlaboratorytestsforacuteandestablishedhivinfectioninsanfrancisco
AT sallyliska performanceofrapidpointofcareandlaboratorytestsforacuteandestablishedhivinfectioninsanfrancisco
AT markwpandori performanceofrapidpointofcareandlaboratorytestsforacuteandestablishedhivinfectioninsanfrancisco
_version_ 1718421457035329536